Recent Anti‐angiogenic Drug Discovery Efforts To Combat Cancer

Abstract

The process of angiogenesis promotes tumor growth and metastatic spreading and angiogenesis inhibition has therapeutic efficacy in many preclinical models. The discovery of pathways mediating tumor angiogenesis, in particular VEGFs and their receptors, paved the way to the development of antiangiogenic drugs to translate into clinic as anti-cancer agents. However, dozens of anti-angiogenic drugs have been approved and routinely used under clinical practice. However, with the compelling preclinical evidence demonstrating anti-cancer activity, therapeutic benefits in patients remained modest. Recent progress in understanding the biology of tumor angiogenesis and their molecular mechanisms opened a new prospect for improving therapeutic strategies. An emergent approach to improve efficacy and avoid resistance is to hit multiple angiogenesis pathways and or administration in combination with other anticancer agents. In this review, we have highlighted some of the emerging aspects and discussed new antiangiogenic drug discovery in the past five years.

Polymer Nanoparticles for Cancer Immunotherapy: Preparation Methods and Applications

“…3 Education and awareness initiatives, tobacco control interventions, immunization against oncogenic viruses, and cancer screening programs are essential elements of the worldwide effort to combat cancer. 4,5 In recent years, the field of cancer immunotherapy has experienced a surge in interest and research, especially in the development of novel nanoparticle-based delivery systems. Polymeric nanoparticles (PNPs) have emerged as promising candidates for targeted drug delivery and immunomodulation in cancer treatment due to their unique properties, such as high loading capacity, tunable size, and surface modification potential.…”